# AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

- Link: https://www.directorstalkinterviews.com/astrazeneca-and-ionis-wainua-misses-phase-iii-attr-cm-trial-endpoint/4121255922
- Published: 2026-07-09T07:26:17+01:00
- Author: Ethan Davis

The CARDIO-TTRansform Phase III trial^(1) for** [AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Ionis’ Wainua (eplontersen) in patients with transthyretin-mediated amyloid 
cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite
outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 
140 weeks compared with placebo. Wainua was generally well tolerated, with a safety
profile consistent with previous results.^(2)

In this contemporary patient population treated with standard of care, including
a majority on a stabiliser,^(3,4) adding Wainua did not provide a statistically 
significant benefit on the composite outcome of CV mortality and recurrent CV events.
In a prespecified subgroup analysis of patients treated with Wainua monotherapy 
as compared to placebo, fewer primary composite events (CV mortality and recurrent
CV events) were observed and this result was nominally significant. In patients 
who were on stabiliser therapy at baseline, no treatment effect was observed.

> **Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, sai**d: “The 
> CARDIO-TTRansform trial was designed to examine the role of Wainua, a gene silencer
> treatment, on top of today’s standard of care in reducing recurring cardiovascular
> events and mortality. Although the trial did not meet its primary objective, we
> believe the results support greater scientific understanding of treatment approaches
> for the hundreds of thousands of patients worldwide suffering from this progressive
> and often fatal condition.”

CARDIO-TTRansform is a Phase III, multicentre, randomised, double-blinded, placebo-
controlled trial^(1) to evaluate the safety and efficacy of Wainua compared to placebo
in participants with ATTR-CM receiving available standard of care: 57% of patients
in each arm received a stabiliser treatment at baseline, and a further 24% in each
arm initiated a stabiliser during the trial.^(3)

AstraZeneca and Ionis will analyse the full data set to further understand the results,
which will be shared with the scientific community at the European Society of Cardiology(
ESC) Congress in August 2026. 

**References:**

1.   ClinicalTrials.gov. CARDIO-TTRansform: A Study to Evaluate the Efficacy and
Safety of Eplontersen in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy(
ATTR CM). Available at: https://clinicaltrials.gov/study/NCT04136171. Accessed July
2026.

2.   AstraZeneca 2023. Wainua (eplontersen) granted first-ever regulatory approval
in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-
mediated amyloidosis. Available at: https://www.astrazeneca.com/media-centre/press-
releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html. Accessed July
2026.

3.   Maurer MS, et al. Design and baseline characteristics of the CARDIO-TTRansform
phase 3 randomised controlled trial of eplontersen for participants with transthyretin
amyloidosis with cardiomyopathy (ATTR-CM). Presented at: Heart Failure Congress 
2026. Heart Failure Congress 2026; 2026 9-12 May 2026; Barcelona, Spain.

4.   Masri A, et al. Rationale and Design of CARDIO-TTRansform, a Phase 3 Tr

Share on:
